Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 445 | 1M | 3M | 736K |
| Gross Profit | 0 | 445 | 1M | 755K | 410K |
| Operating Income | -36K | -229K | -1M | -8M | -4M |
| EBITDA | -116K | 253K | -1M | -8M | -5M |
| Net Income | -709K | -2M | -2M | -14M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.024
+0.00% today
1Y Change
+716.67%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pure Harvest Corporate Group, Inc. (PHCG) is a Healthcare stock with listed on OTC. The stock last traded around $0.02 and up 716.7% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +854.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +854.0%, free cash flow +2633.7% with operating margin 0.0% and ROIC 7.0%. Valuation is more restrained than many high-expectation growth names at P/E 0.3. Stock Foundry combines PHCG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHCG
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PHCG Max Drawdown
-73.33%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PHCG and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$735.7K
-71.0% YoY
FY Net Income
-$6.3M
+54.6% YoY
Free Cash Flow
-$2.4M
+50.4% YoY
Revenue Growth
+0.0%
EPS Growth
+854.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 445 | 1M | 3M | 736K |
| Gross Profit | 0 | 445 | 1M | 755K | 410K |
| Operating Income | -36K | -229K | -1M | -8M | -4M |
| EBITDA | -116K | 253K | -1M | -8M | -5M |
| Net Income | -709K | -2M | -2M | -14M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3K | 643K | 224K | 857K | 2M |
| Total Assets | 3K | 9M | 9M | 11M | 5M |
| Total Liabilities | 8M | 10M | 10M | 7M | 1M |
| Shareholder Equity | -8M | -1M | -1M | 4M | 3M |
| Total Debt | 5M | 6M | 5M | 4M | 1M |
| Net Debt | 5M | 5M | 5M | 3M | -573K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
+55.5% YoY
Capital Expenditures
279K
-263.5% YoY
Free Cash Flow
2M
+50.4% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-95.0%
Debt / Equity
-0.39x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.